PresentationMeg AlexanderCEO, President & Director Good morning, everyone, and welcome to Ovid Therapeutics where we are on a journey to pioneer better and gentler medicines for the brain. And one of the ways we're doing that is with what we think is a portfolio of mechanisms for a very exciting target in the brain, KCC2, which stands for potassium-chloride co-transporter 2. And while we've had a lot of progress in our epilepsy pipeline, there has also been tremendous progress in our KCC2 portfolio. So we'r ...